Results 121 to 130 of about 226,969 (309)

Enhanced patient selection with quantitative continuous scoring of PD-L1 expression for IO treatment in metastatic NSCLC

npj Precision Oncology
Immune checkpoint inhibitors targeting PD-1/PD-L1 are approved for metastatic non-small-cell lung cancer treatment. In clinical practice, the treatment choice depends on visual scoring of PD-L1, which is subjective and semi-quantitative. In this work, we
J. Lesniak, M. Schick, T. Kunzke, F. Pollastri, J. P. Vigueras-Guillén, H. Hessel, S. Haneder, P. Sontakke, K. DaCosta, R. Alleze, J. Zimmermann, A. Kapil, N. Brieu, A. Shumilov, H. Sade, J. C. Barrett, G. Schmidt, R. Stewart   +17 more
doaj   +1 more source

Geminal Difunctionalization of Ketones via C─S Bond Insertion of Photogenerated Donor–Donor Diazo Compounds

Angewandte Chemie International Edition, EarlyView.
Geminal difunctionalization of readily available building blocks provides rapid access to molecular complexity. This work introduces a strategy for installing two distinct functional groups on a carbonyl carbon by transforming it into a donor–donor diazo compound, enabling both batch and flow applications with broad solvent compatibility.
Vincent George, Aryaman Pattanaik, Daniel Maddox, Lukas M. Sigmund, Giovanna Mejia, Sara Pahlén, Simon O. Angerer, Maria Schmoll, Lisa Marie Schneider, Nidhal Selmi, Mikhail Kabeshov, Giulia Bergonzini, Julia Rehbein, Burkhard König   +13 more
wiley   +1 more source

The interplay between FOXO3 and FOXM1 influences sensitivity to AKT inhibition in PIK3CA and PIK3CA/PTEN altered estrogen receptor positive breast cancer

npj Breast Cancer
Loss of PTEN expression, via homozygous or hemizygous deletion, is common in PIK3CA mutant ER + BC tumors. We assessed reduction of PTEN protein expression on AKT inhibitor capivasertib efficacy in PIK3CA altered tumors.
Valentina Cutano, Ming Li Chia, Eleanor M. Wigmore, Lorna Hopcroft, Stuart C. Williamson, Amanda L. Christie, Brandon Willis, James Kerr, Jenny Ashforth, Rhys Fox, Sophie D’Arcy, Lauren Bradshaw, Catherine Blaker, Cath Eberlein, Lambert Montava-Garriga, Elza C. de Bruin, Susan E. Critchlow, Kevin M. Brindle, Simon T. Barry, Susana Ros   +19 more
doaj   +1 more source

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study

Arthritis &Rheumatology, EarlyView.
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate to severe systemic lupus erythematosus (SLE) activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly
Susan Manzi, Ian N. Bruce, Eric F. Morand, Richard Furie, Yoshiya Tanaka, Kenneth C. Kalunian, Anca Askanase, Patricia Puzio, Emon Khan, Jenny Wissmar, Michael Song, Catharina Lindholm, for the TULIP‐SC investigators   +12 more
wiley   +1 more source

Anifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results From the Phase 2 Randomized Trial

Arthritis &Rheumatology, EarlyView.
Objective Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE) and is partially driven by type I interferon signaling. Anifrolumab, an approved treatment for patients with SLE, has been investigated in a phase 2 trial in patients with LN receiving standard therapy (TULIP‐LN, ClinicalTrials.gov identifier ...
Andrea Fava, Michelle Petri, Patrick G. Gavin, Eszter Csomor, Philip Z. Brohawn, Daniel Muthas, Adam Platt, Catharina Lindholm, Nicola Ferrari   +8 more
wiley   +1 more source

Multi‐Omic Profiling Reveals Immune Cell Priming Signature Linked to Lupus Prognosis

Arthritis &Rheumatology, EarlyView.
Objective Systemic lupus erythematosus (SLE) is a multiorgan disease with widespread immune dysregulation and significant unmet clinical need. Blood‐based gene expression studies have advanced our understanding of SLE pathogenesis but may overlook critical tissue‐specific mechanisms that drive disease heterogeneity and progression.
Michael A. Smith, Dominic Sinibaldi, Saifur Rahman, Chia‐Chien Chiang, Anna M. Hansen, Jill Henault, Carlos P. Roca, Shu Wang, Kamelia Zerrouki, Rebecca Filippi, Christopher Groves, Zerai Manna, Jun Chu, Michael Davis, Sarthak Gupta, Christopher Morehouse, Melissa de los Reyes, Rachel Ettinger, Roland Kolbeck, Mariana J. Kaplan, Miguel A. Sanjuan, Richard M. Siegel, Sarfaraz A. Hasni, Kerry A. Casey   +23 more
wiley   +1 more source

autoscoRA: Deep Learning to Automate Sharp/van der Heijde Scoring of Radiographic Damage in Rheumatoid Arthritis

Arthritis &Rheumatology, Accepted Article.
Objective Regular imaging by conventional radiography to assess for joint damage is a cornerstone in the management of rheumatoid arthritis (RA). Scoring systems to quantify such damage, such as the widely used Sharp/van der Heijde (SvdH) score, are limited by the requirement of time and experienced staff as well as intra‐ and inter‐rater variability ...
Thomas Deimel, Paul J. Weiser, Martin Urschler, Christian Payer, Peter Mandl, Georg Langs, Daniel Aletaha   +6 more
wiley   +1 more source

Transient Transfection of Rolling‐Circle Amplified DNA in Biomanufacturing‐Relevant Mammalian Cell Lines: A Comparison of Transfection Conditions for Optimal Protein Expression

Biotechnology and Applied Biochemistry, EarlyView.
ABSTRACT Rolling‐circle amplification (RCA) is a completely synthetic and rapid mechanism for scaling‐up bulk DNA that eliminates requirements for large‐scale bacterial fermentation. Several reports have described the surprising ability of large unprocessed (hyperbranched) rolling circle‐amplified DNA (RCA DNA) to effectively transfect cultured cells ...
Evelina Loghin, Erik Kvam, Lisa Lowery, Nathan Hudson, Jenny Keen, Brian Davis, Roger B. Dodd, Christine Surrette, John Nelson   +8 more
wiley   +1 more source

Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models

npj Breast Cancer, 2023
Lorna Hopcroft, Eleanor M. Wigmore, Stuart C. Williamson, Susana Ros, Cath Eberlein, Jennifer I. Moss, Jelena Urosevic, Larissa S. Carnevalli, Sara Talbot, Lauren Bradshaw, Catherine Blaker, Sreeharsha Gunda, Venetia Owenson, Scott Hoffmann, Daniel Sutton, Stewart Jones, Richard J. A. Goodwin, Brandon S. Willis, Claire Rooney, Elza DeBruin, Simon T. Barry   +20 more
doaj   +2 more sources

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source